Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with ...

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory ...

A dietary change that included a decrease in dietary omega-6 and an increase in omega-3 fatty acids could reduce prostate ...

Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...

with levels increasing after discontinuing sargramostim a GM-CSF = granulocyte-macrophage colony-stimulating factor; BCG = bacillus Calmette-Guérin vaccine; RR = response rate, including complete ...

We identified several polarization states of macrophages in synovium following joint injury, underpinned by distinct transcriptomic signatures, and regulated in part by stromal-derived macrophage ...

From Trump’s Ukraine proposals to JD Vance’s Munich speech, it’s clear that the US wants to rule like an empire. By Bruno Maçães Donald Trump and his Secretary of Defence, former Fox News television ...

The intervention group showed reduced triglyceride levels and macrophage colony-stimulating factor, with no change in tumor volume or PSA. Further studies, including phase 3 and longer-term trials, ...